CapsoVision (CV) Asset Writedowns and Impairment (2024)

CapsoVision's (CV) quarterly Asset Writedowns and Impairment came in at $7000.0 in Q4 2024, up 600.0% quarter-over-quarter from $1000.0 in Q3 2024.

CapsoVision (CV) Asset Writedowns and Impairment (2024) Analysis & Trends

CapsoVision has disclosed Asset Writedowns and Impairment across 1 years of filings, most recently posting $7000.0 for Q4 2024.

Asset Writedowns and Impairment for Q4 2024 came in at $7000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $8000.0 (changed N/A YoY), and the FY2025 annual result was $11000.0, up 37.5% from the prior year.
Asset Writedowns and Impairment came in at $7000.0 for Q4 2024 at CapsoVision, up from $1000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $7000.0 in Q4 2024 to a low of $1000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	CapsoVision	161.82 Mn	151.71 Mn	1.95 Mn

Download Data